Background
Breast cancer is the most common cancer among women globally, with triple-negative breast cancer (TNBC) being the most aggressive type. In India, TNBC makes up about one-third of all breast cancer cases. While adding pembrolizumab to standard chemotherapy has shown benefits, many patients in low- and middle-income countries cannot access this treatment due to its high cost. Research suggests that a lower dose of pembrolizumab might still be effective, but no clinical trials have been conducted yet for TNBC patients.
Study Overview
This study is a phase II clinical trial that involves two groups of patients. One group will receive standard chemotherapy, while the other group will receive a lower dose of pembrolizumab along with chemotherapy. The main goal is to see if the lower dose helps improve the overall response to treatment. Secondary goals include measuring how long patients remain free of invasive disease and assessing their quality of life.
Potential Benefits
The PLANeT trial aims to determine if low-dose pembrolizumab combined with chemotherapy can improve treatment outcomes for women with TNBC. If successful, this approach could provide better access to effective treatment for those who currently cannot afford it.
Measurable Outcomes
Clear goals for clinics and patients include:
- Improvement in pathological complete response rates
- Increased invasive disease-free survival
- Enhanced quality of life for patients
AI Tools for Clinical Needs
Select AI solutions that are tailored to specific tasks in medical management, ensuring they align with the study’s objectives and outcomes.
Implementation Strategy
Start with a pilot project using AI tools to track results from the trial. Monitor the real-world impact of the therapy and adjust strategies as needed based on data collected.
Contact Us
For AI solutions in medical management, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
